Compare BFS & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFS | CDNA |
|---|---|---|
| Founded | 1993 | 1998 |
| Country | United States | United States |
| Employees | 98 | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 809.1M | 1.1B |
| IPO Year | N/A | 2007 |
| Metric | BFS | CDNA |
|---|---|---|
| Price | $33.67 | $20.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $44.00 | $28.00 |
| AVG Volume (30 Days) | 40.5K | ★ 600.1K |
| Earning Date | 05-11-2026 | 04-28-2026 |
| Dividend Yield | ★ 6.92% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | $0.30 | $16.01 |
| Revenue Next Year | $5.67 | $11.31 |
| P/E Ratio | ★ $30.48 | $412.00 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $29.16 | $10.96 |
| 52 Week High | $35.45 | $23.24 |
| Indicator | BFS | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 44.32 | 51.42 |
| Support Level | $33.14 | $16.63 |
| Resistance Level | $34.99 | $21.42 |
| Average True Range (ATR) | 0.81 | 1.35 |
| MACD | -0.15 | -0.22 |
| Stochastic Oscillator | 30.82 | 48.05 |
Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: Shopping Centers segment, which contribute the maximum portion of total revenue; and mixed-use properties.Mixed-Use Properties segment include office, retail and multi-family residential use.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.